drugset / Trial / NCT00627627
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.
Timeline
- Start
- 2008-04
- Primary completion
- 2010-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | retaspimycin | Small molecule | 400 mg/m2 | Intravenous |